FoxBio develops engineered regulatory T cells (CAR-Tregs), the next generation of personalized medicine.
The Science behind
CAR-Treg
The immune system must balance protection (fighting infections) and regulation (preventing autoimmunity). Regulatory T cells (Tregs) are the key immune regulators, ensuring that inflammation does not spiral out of control through multiple mecanism of action. FoxBio’s CAR-Tregs leverage this natural mechanism, creating a precise therapy that rebalances immunity without broad suppression. This approach transforms how we treat autoimmune diseases, offering a more targeted and effective solution.
CAReREG: proprietary production platform
CAReReg is a cutting-edge CAR-Treg platform delivering a safe and effective therapeutic product, built on robust activation with strong immunosuppressive function, very low immunogenicity, low tonic signaling, and no cellular exhaustion. It generates a pure and stable CAR-Treg population that remains effective in inflammatory environments, ensuring reliable and consistent therapeutic performance. The platform is clinically validated, with multiple successful productions already delivered to patients, demonstrating its technological maturity and translational readiness.
Our first clinical candidate targets a master regulator of inflammation validated in numerous diseases (Crohn’s, psoriasis, ulcerative colitis, spondyloarthritis).
Contact us
